FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma
A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.
Related Articles
FDA approves mirdametinib for adult and pediatric patients with neurof
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years…
Pediatric Track offers timely updates on complex conditions in children – Tandem Meetings News
A full day of programming is dedicated to the tailored treatments that are required to care for this uniquely vulnerable patient population, explains Michael Verneris,…
Reprogramming Compromised Immune Cells to Fight Cancer – News Center
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to work against tumors, according to a study published in Science Advances.
Blood Podcast | Blood | American Society of Hematology
Blood Podcast | Blood | American Society of Hematology Blood Podcast The editors of Blood are pleased to introduce a podcast series, published weekly…
Olutasidenib and Azacitidine Combination Expands Options for mIDH1 Relapsed or Refractory AML | Blood Cancers Today
Durable remissions were shown in patients with high-risk, relapsed or refractory, IDH1-mutant AML treated with combination of olutasidenib plus azacitidine in multiple studies.
Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival
A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained…
How I treat blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm is a rare but aggressive malignancy that arises from precursors of plasmacytoid dendritic cells and typically
FDA Greenlights Mirdametinib in Adult and Pediatric NF1-PN
The FDA approved mirdametinib for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.
“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender Medical group sues over removing “information used every day by health professions” – The Cancer Letter
The web page for the FDA Office of Minority Health and Health Equity is no more. To access this subscriber-only content please log in or…
